Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
Rebecca H HabermanRamin HeratiDavid SimonMarie SamanovicRebecca B BlankMichael TuenSergei B KoralovRaja AtreyaKoray TascilarJoseph R AllenRochelle CastilloAmber R CorneliusPaula RackoffGary SolomonSamrachana AdhikariNatalie AzarPamela RosenthalPeter IzmirlyJonathan SamuelsBrian GoldenSoumya M ReddyMarkus F NeurathSteven B AbramsonLarissa Valor-MéndezMark J MulliganJose U ScherPublished in: Annals of the rheumatic diseases (2021)
In two independent cohorts of patients with IMID, methotrexate, a widely used immunomodulator for the treatment of several IMIDs, adversely affected humoral and cellular immune response to COVID-19 mRNA vaccines. Although precise cut-offs for immunogenicity that correlate with vaccine efficacy are yet to be established, our findings suggest that different strategies may need to be explored in patients with IMID taking methotrexate to increase the chances of immunisation efficacy against SARS-CoV-2 as has been demonstrated for augmenting immunogenicity to other viral vaccines.